

Efficient and simple one-pot conversion of resin-bound *N*-Fmoc amino acids and dipeptides into *N*-Boc derivatives

Ricardo L. E. Furlán^a and Ernesto G. Mata^b

^aArea Farmacognosia - ^bInstituto de Química Orgánica de Síntesis (CONICET - UNR),
Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha
531, 2000 – Rosario, Argentina
E-mail: rfurlan@fbioyf.unr.edu.ar; emata@fbioyf.unr.edu.ar

**Dedicated to Professor Edmundo A. Rúveda on his 70th birthday
and Professor Roberto A. Rossi on his 60th birthday**
(received 15 Feb 03; accepted 10 Apr 03; published on the web 25 Apr 03)

Abstract

Wang resin bound *N*-fluorenylmethoxycarbonyl (Fmoc) amino acids and dipeptides were efficiently converted into the corresponding *N*-*tert*-butoxycarbonyl (Boc) derivatives using two different “one-pot” procedures: potassium fluoride / di-*tert*-butyl carbonate and potassium fluoride / *tert*-butyl S-(4,6-dimethylpyrimidin-2-yl) thiocarbonate.

Keywords: Solid-phase synthesis, Boc carbamates, Fmoc carbamates, Amino acids and derivatives, dipeptides


Introduction

Despite the proliferation of protecting groups, functional group incompatibility remains a key issue in synthetic organic chemistry.¹ The problem is particularly delicate in the design and synthesis of polyfunctional molecules such as peptides, oligosaccharides, glycopeptides, glycolipids, nucleotides, and polyketides.

The emergence of solid-phase chemistry² has added a new element of complexity due to the different requirements and properties of the two phases.³ The *N*-fluorenylmethoxycarbonyl (Fmoc) and *N*-*tert*-butoxycarbonyl (Boc) groups are two of the most common protecting groups in solid-phase chemistry, with a large number of building blocks available containing them.⁴ They display contrasting chemical stabilities: *N*-Fmoc is usually cleaved by organic bases whereas *N*-Boc is stable to bases but removed in acidic medium. The increasing degree of sophistication of the solid-phase chemistry raises the problem of incompatibility of *N*-Fmoc protection to different reagents.⁵ Moreover, *N*-Boc protecting group has proven to be better than *N*-Fmoc after five or six steps in the solid-phase synthesis of the “difficult” peptides, since acid

deprotection may destroy undesirable β -sheet structures.⁶ Therefore, the development of solid-phase methodologies for one-pot conversion of *N*-Fmoc carbamates into *N*-Boc carbamates under mild conditions is highly desirable.

A number of papers have appeared describing solution-phase examples of one-pot interconversion of carbamates, such as transformation of *N*-benzyloxycarbonyl (Cbz) group into Boc group^{7,8} or Fmoc group,⁹ conversion of *N*-fluorenylmethoxycarbamates into Boc group¹⁰ or Cbz group,¹¹ conversion of Boc into Cbz,^{12,13} and transprotection of *N*-allyloxycarbonyl (Aloc) to Boc group.¹⁴ (Scheme 1). However, the interconversion of carbamates in solid-phase chemistry is still unusual.¹⁵



(a) Ref. 7 and 8, (b) Ref. 12 and 13, (c) Ref. 9, (d) Ref. 10, (e) Ref. 11, (f) Ref. 14.

Scheme 1. Solution-phase interconversion of carbamates.

In this publication, we describe the efficient one-pot conversion of Wang resin bound *N*-Fmoc amino acids and dipeptides into the corresponding *N*-Boc derivatives.¹⁶

Results and Discussion

Transprotection reactions were carried out combining a base and a *tert*-butoxycarbonylating reagent. To cleave the Fmoc group we used fluoride ion; which has proven to be very efficient for the non-hydrolytic solution-phase cleavage of Fmoc carbamates.^{1,17} In addition, its presence in the reaction medium should not interfere with the *tert*-butoxycarbonylation step. We choose the potassium salt since it does not affect ester groups usually unstable in the presence of the generally used tetrabutylammonium fluoride.¹⁰

For reprotection we used three different ready-to-use *tert*-butoxycarbonylating agents: 1,2,2,2-tetrachloroethyl *tert*-butyl carbonate,¹⁸ di-*tert*-butyl dicarbonate,¹⁹ and *tert*-butyl S-(4,6-dimethylpyrimidin-2-yl) thiolcarbonate (Boc-S).²⁰

Monitoring reactions represents one of the major drawbacks of solid-phase chemistry.²¹ In order to examine the progress of the reaction, we first carried out the transprotection of Fmoc-Ala-OMe in solution. Using five equivalents of potassium fluoride and three equivalents of carbonylating agent (1,2,2,2-tetrachloroethyl *tert*-butyl carbonate or di-*tert*-butyl dicarbonate) in DMF yielded the Boc-protected product quantitatively in 5-7 hours at room temperature. Interestingly, no free amine was detected by TLC suggesting that deprotection of the amine group is the limiting step of the process rather than the Boc reprotection. Therefore, the amount of unreacted fluorenylmethoxycarbamate present in the reaction mixture can be regarded as an indication of the reaction progress.

Consequently, we next carried out the solid-phase transprotection of Fmoc-Phe-Wang resin using the combination potassium fluoride / di-*tert*-butyl dicarbonate in DMF. The amount of unreacted Fmoc group at different times was determined as "Fmoc loading" in small portions of resin by cleaving the carbamate with piperidine followed by UV quantitation of the resulting piperidine-dibenzylfulvene adduct at 301 nm.²² In this way, it was possible to estimate the reaction time required for complete interconversion of the Fmoc group into Boc group (Figure 1).





Figure 1. Solid-phase transprotection of Fmoc-Phe-Wang resin. UV determination of unreacted Fmoc group on the resin.

To corroborate that the deprotected amine had in effect been reprotected *in situ* as Boc-carbamate, the product was detached from the solid support using trimethyltin hydroxide (TMTOH), which produces the selective cleavage of the benzyl ester link to the resin without affecting the *tert*-butoxycarbamate (Scheme 2).^{23,24} The yield for the entire process (Fmoc deprotection, Boc protection, and cleavage from the solid support) was 95%.

In order to evaluate the scope of the reaction, the methodology was applied to the solid phase transprotection of a variety of Wang resin-bound amino acids and dipeptides (Table 1). Using the combination KF / Boc₂O, the Fmoc carbamates were smoothly converted into Boc carbamates in high overall yields for the isolated products.

**Scheme 2.** Final detachment of Boc-Phenylalanine from Wang resin.**Table 1.** Solid-phase conversion of Fmoc carbamates into Boc carbamates^a

Entry	Substrate	Product	KF/Boc ₂ O Yield(%) ^b	KF/Boc-S Yield(%) ^b
1	Fmoc-Ala-Wang resin	Boc-Ala-OH	94	100
2	Fmoc-Leu-Wang resin	Boc-Leu-OH	96	100
3	Fmoc-Ser(O ^t Bu)-Wang resin	Boc-Ser(O ^t Bu)-OH	100	85
4	Fmoc-Boc-Lys-Wang resin	(Boc) ₂ -Lys-OH	86	80
5	Fmoc-Cys(<i>p</i> -MeOBn)-Wang resin	Boc-Cys(<i>p</i> -MeOBn)-OH	88	100
6	Fmoc-Pro-Wang resin	Boc-Pro-OH	72	57
7	Fmoc-Phe-Wang resin	Boc-Phe-OH	95	100
8			100	100
9			74	83
10			81	76
11			64	78

^aAll reactions were carried out according to the general procedure described in experimental section. ^bOverall isolated yield, based on the initial loading level of Fmoc-AA-Wang resin or Fmoc-AA-AA-Wang resin (three steps).

Functionalities such as *tert*-butyl ether, *p*-methoxybenzyl thioether, and amide were stable to the reaction conditions. No loss of enantiomeric purity was detected after comparing optical rotations of representative products with reported values.

Among the various reagents proposed to effect Boc protection, *tert*-Butyl S-(4,6-dimethylpyrimidin-2-yl) thiolcarbonate (Boc-S) has been widely recognised as the better alternative to Boc₂O. In order to test its capability to perform the solid-phase reprotection of the amine group, the same set of Wang resin-bound amino acids and dipeptides were treated with the combination of KF / Boc-S (Table 1). Yields were similar to those previously achieved with Boc₂O, indicating that both *tert*-butoxycarbonylating agents can be used indiscriminately. Again, no sign of racemization was detected.

Despite the promising results in solution-phase studies, our attempts to use 1,2,2,2-tetrachloroethyl *tert*-butyl carbonate for the solid-phase *tert*-butoxycarbonylation were unsuccessful. When the Fmoc-Ala-Wang resin was treated through a one-pot procedure with the tandem KF / 1,2,2,2-tetrachloroethyl *tert*-butyl carbonate, no Fmoc carbamate was detected on the solid support after 24 h. However, Boc reprotection did not occur and the final detachment of the resin-bound product with TMOH mainly yielded *N*-deprotected alanine.

Conclusions

In summary, we describe an efficient methodology for the one-pot conversion of Wang resin bound *N*-Fmoc amino acids and dipeptides into the corresponding *N*-Boc derivatives, using two different *tert*-butoxycarbonylating agents: di-*tert*-butyl dicarbonate (Boc₂O) and *tert*-butyl S-(4,6-dimethylpyrimidin-2-yl) thiolcarbonate (Boc-S). This approach could find applicability not only for those wishing to synthesize peptide residues appropriate to solid-phase peptide synthesis (SPPS), but also in the field of combinatorial chemistry, particularly in the solid-phase synthesis of small molecule libraries. The Boc protecting group has some advantages compared to the Fmoc protecting group due to its stability under basic conditions. Replacement of an Fmoc carbamate by a Boc carbamate could be necessary and a one-pot conversion would facilitate this process by eliminating additional reaction steps.

Experimental Section

General Procedures. NMR spectra were measured in CDCl₃ or DMSO-d₆ at 200 MHz for protons and 50 MHz for ¹³C, and recorded on a Bruker AC-200 spectrometer. Infrared spectra were taken on a Beckman AccuLab 8 spectrophotometer. Optical rotations were measured with a Jasco DIP-1000 polarimeter at ambient temperature using a 1-mL capacity cell. UV absorbance was measured on a Beckman DU 640 spectrophotometer. TLC and spectral analyses (IR, ¹H and ¹³C NMR) indicated that products were identical with commercial authentic material. *N*-

protected amino acids were purchased from Calbiochem-Novabiochem Corp. Fmoc-dipeptides were synthesized using conventional Fmoc-chemistry.

Solid phase transprotection of Fmoc group into Boc group

KF/Boc₂O. Typical procedure. To a stirred suspension of Fmoc-AA-Wang resin (0.099 mmol) in DMF (1.3 mL) under nitrogen, KF (59 mg, 1.01 mmol) and Et₃N (31 μ L, 0.22 mmol) were added. The mixture was kept at room temperature and di-*tert*-butyl dicarbonate (Boc₂O) (28.37 mg, 0.13 mmol) was added. The reaction mixture was stirred until no Fmoc attached to the resin was detected by UV (24 h). The resin was filtered out, washed successively with DMF, HCl 1N, 5% NaHCO₃, H₂O, MeOH, AcOEt, CHCl₃ and MeOH, and dried overnight at reduced pressure.

KF/Boc-S. Typical procedure. To a stirred suspension of Fmoc-AA-Wang resin (0.078 mmol) in DMF (1.5 mL) under nitrogen, KF (39 mg, 0.67 mmol) and Et₃N (40 μ L, 0.234 mmol) were added at room temperature. Then, a solution of *tert*-butyl S-(4,6-dimethylpyrimidin-2-yl) thiolcarbonate (Boc-S) (58.1 mg, 0.284 mmol) in DMF (1 mL) was added. The reaction mixture was stirred until no Fmoc attached to the resin was detected by UV (24 h). The resin was filtered out, washed successively with DMF, HCl 1N, 5% NaHCO₃, H₂O, MeOH, AcOEt, CHCl₃ and MeOH, and dried overnight at reduced pressure.

The transprotection reaction was monitored by estimating the amount of unreacted Fmoc on the resin expressed as Fmoc loading.

Typical procedure. 3-8 mg of resin were filtered out and washed with DMF, HCl 1N, 5% NaHCO₃, H₂O, MeOH, AcOEt, CHCl₃ and MeOH. The resin was dried at reduced pressure and accurately weighed out into a measuring flask. 20% piperidine in DMF (25 mL) was added, the resulting mixture was stirred for 20 min and centrifuged. Three readings of the 300nm absorbance of the supernatant were taken and their average was introduced in the following equation to obtain the Fmoc loading of the resin.

$$\frac{\text{UV reading} \times 25 \times 1000}{7800 \times \text{wt of resin in mg}} = \text{Fmoc loading in mmol / g of resin}$$

Cleavage of Boc protected amino acids and dipeptides

Typical procedure. To a stirred suspension of resin (0.22 mmol of Fmoc protected amino acid or dipeptide) in 2.5 mL of (CH₂Cl)₂ was added TMTOH (0.154 g, 0.56 mmol) at room temperature under nitrogen. The reaction mixture was then refluxed (83°C) for 9 h and the resulting suspension filtered and washed successively with (CH₂Cl)₂, CH₂Cl₂, MeOH and AcOEt. The combined organic solution was evaporated to dryness under reduced pressure and the resultant residue was dissolved in 20 mL of AcOEt and washed successively with diluted aqueous solution of HCl (5 x 6 mL), water (1 x 6) and Brine (1 x 6). Therefore, it was extracted with 5% NaHCO₃ solution (3 x 7 mL), the combined aqueous solution was acidified to pH 3-4 with 2.5 N H₂SO₄ solution and extracted with AcOEt (3 x 11 mL). The AcOEt solution was dried (Na₂SO₄) and evaporated to dryness. In all cases the ¹H NMR analysis of the crude reaction product

showed only the corresponding *N*- α -Boc-L-amino acid or dipeptide. No other product was detected by ^1H NMR.

***N*- α -Boc-L-alanine.** see ref. 24.

***N*- α -Boc-L-leucine.** $[\alpha]^{20}_{\text{D}} -29.8$ (*c* 1.0 in AcOH) [lit.²⁵ -30 (*c* 1.0 in AcOH)]. IR (film) ν 3340, 3320 (N-H, urethane), 3000 (O-H, COOH), 1760 ($\nu\text{C=O}$, carboxylic, dimer), 1710 (C=O , carboxylic, monomer), 1680 (C=O , urethane), 1530 cm^{-1} (amide II band). ^1H RMN (CDCl_3) δ 0.96 (d, 6H, *J* = 6.2 Hz, Me), 1.45 (s, 9H, Me), 1.40-1.85 (m, 3H, CH_2 , CH), 4.30 (br s, 1H, CH), 4.90 (br s, 1H, NH). ^{13}C RMN (CDCl_3) δ 21.7, 22.7 ($\text{C}\delta$), 24.66 ($\text{C}\gamma$), 28.18 (Me, Boc), 41.37 ($\text{C}\beta$), 51.98 ($\text{C}\alpha$), 80.05 (C, Boc), 156.00 (C=O , Boc), 177.86 (COOH).

***N*- α -Boc-O-*tert*-butyl-L-serine.** IR (film) ν 3000 (O-H, COOH), 1730-1660 (C=O , COOH and urethane), 1530 cm^{-1} (amide II band). ^1H RMN (CDCl_3) δ 1.20 (s, 9H, Me), 1.46 (s, 9H, Me), 3.54 (dd, AB system, *J* = 8.80 and 5.4 Hz, 1H, CH_2), 3.84 (dd, AB system, *J* = 8.80 and 5.3 Hz, 1H, CH_2), 4.37 (br s, 1H, CH), 5.34 (d, *J* = 7.82 Hz, 1H, NH). ^{13}C RMN (CDCl_3) δ 27.14 (Me, *t*-Bu), 28.17 (Me, Boc), 53.82 ($\text{C}\alpha$), 61.62 ($\text{C}\beta$), 73.90 (C, *t*-Bu), 80.05 (C, Boc), 155.65 (C=O , Boc), 175.06 (COOH).

***N* α -Boc-N ϵ -Boc-L-lysine.** IR (film) ν 3370 (N-H), 3000 (O-H, COOH), 1730 (C=O , COOH), 1700 (C=O , urethane), 1530 cm^{-1} (amide II band). ^1H RMN (CDCl_3) δ 1.44 (s, 18H, Me), 1.40-1.90 (m, 6H, CH_2), 3.11 (br s, 2H, CH_2), 4.13 (br s, 1H, CH), 4.80 (br s, 1H, NH), 5.44 (br s, 1H, NH). ^{13}C RMN (CDCl_3) δ 22.39 ($\text{C}\gamma$), 28.30 (6C, Me, Boc), 29.37 ($\text{C}\beta$), 32.02 ($\text{C}\delta$), 40.13 ($\text{C}\epsilon$), 53.43 ($\text{C}\alpha$), 79.18 (C, Boc), 79.75 (C, Boc), 155.66 (C=O , Boc), 156.00 (C=O , Boc), 175.97 (COOH).

***N*- α -Boc-S-*p*-methoxybenzyl-L-cysteine.** see ref. 24.

***N*- α -Boc-L-proline.** see ref. 24.

***N*- α -Boc-L-phenylalanine.** $[\alpha]^{20}_{\text{D}} +23.7$ (*c* 1.5 in EtOH) [lit.²⁵ +23.7 (*c* 1.5 in EtOH)]. IR (film) ν 3340-3300 (N-H, urethane), 3000 (O-H, COOH), 1735-1660 cm^{-1} (C=O , COOH, urethane). ^1H RMN (CDCl_3) δ 1.40 (s, 9H, Me), 2.90-3.15 (m, 2H, CH_2), 4.60 (br s, 1H, CH), 4.95 (br s, 1H, NH), 7.22 (m, 5H, Ar). ^{13}C RMN (CDCl_3) δ 28.13 (Me, Boc), 37.71 and 38.98 ($\text{C}\beta$), 54.21 and 55.95 ($\text{C}\alpha$), 80.11 and 81.39 (C, Boc), 126.86 ($-\text{CH}$, Ar), 128.41 (2C, CH, Ar), 129.29 (2C, CH, Ar), 135.82 and 136.34 (C, Ar), 155.27 and 156.31 (C=O , Boc), 175.85 and 176.19 (COOH). (double signals are observed because of hydrogen bond formation).

***N*- α -Boc-L-proline-L-phenylalanine.** IR (film) ν 3000 (O-H, COOH), 1720-1660 cm^{-1} (C=O , COOH and urethane). ^1H RMN (CDCl_3) δ 1.40 (s, 9H, Me), 1.70-2.10 (m, 4H, CH_2), 3.00-3.45 (m, 4H, $\text{CH}_2\text{-N}$, $\text{CH}_2\text{-Ph}$), 4.28 (br s, 1H, CH), 4.86 (m, 1H, CH), 7.23 (m, 6H, Ph, NH). ^{13}C RMN (CDCl_3) δ 26.42 ($\text{C}\gamma$, Pro), 30.60 (Me, Boc), 31.90 ($\text{C}\beta$, Pro), 39.96 ($\text{C}\beta$, Phe), 49.21 ($\text{C}\delta$, Pro), 55.25 ($\text{C}\alpha$, Phe), 63.39 ($\text{C}\alpha$, Pro), 83.18 (C, Boc), 129.37 (CH, Ar), 130.71 (2C, CH, Ar), 131.59 (2C, CH, Ar), 138.51 (C, Ar), 157.78 (C=O , Boc), 174.77 and 176.39 (C=O).

***N*- α -Boc-O-*tert*-butyl-L-serine-L-phenylalanine.** ^1H RMN (CDCl_3) δ 1.14 (s, 9H, Me), 1.43 (s, 9H, Me), 3.13 (m, 2H, CH_2), 3.38 (br s, 1H, CH_2), 3.74 (br s, 1H, CH_2), 4.16 (br s, 1H, CH), 4.86 (br s, 1H, CH), 5.44 (br s, 1H, NH), 7.15-7.30 (m, 5H, Ph). ^{13}C RMN (CDCl_3) δ 27.19 (Me, *t*-BuO), 28.16 (Me, Boc), 37.42 ($\text{C}\beta$, Phe), 53.17 ($\text{C}\alpha$, Ser), 54.25 ($\text{C}\alpha$, Phe), 61.55 ($\text{C}\beta$, Ser),

74.04 (C, *t*-BuO), 80.21 (C, Boc), 127.04, 128.49, 129.9 (CH, Ar), 135.62 (C, Ar), 155.51 (C=O, Boc), 170.78 and 174.41 (C=O).

***N*- α -Boc-L-alanine -S-*p*-methoxybenzyl-L-cysteine.** ^1H RMN (CDCl_3) δ 1.35 (d, 3H, $J = 7$ Hz, Me); 1.42 (s, 9H, Me); 2.90 (dq, $J = 14.0$ Hz, $J = 5.9$ Hz, $J = 4.9$ Hz, 2H, $\text{CH}_2\text{-S}$); 3.67 (s, 3H, OMe); 4.29 (br s, 1H, CH); 4.75 (m, 1H, CH); 5.33 (br s, 1H, NH); 6.82 (d, $J = 8.6$ Hz, 2H, Ar); 7.10 (br s, 1H, NH); 7.20 (d, $J = 8.6$ Hz, 2H, Ar).

***N*- α -Boc-L-alanine-L-leucine.** ^1H RMN (CDCl_3) δ 0.92 (bd, 6H, Me, Leu); 1.35 (d, $J = 7$ Hz, 3H, Me, Ala); 1.43 (s, 9H, Me); 1.42-1.80 (m, 3H, CH_2 , CH, Leu); 4.20 (br s, 1H, CH,); 4.60 (br s, 1H, CH); 5.26 (br s, 1H, NH); 5.79 (br s, 1H, COOH); 6.82 (br s, 1H, NH). ^{13}C NMR (CDCl_3) δ 17.7 (Me, Ala), 21.6, 22.8 (Me, $\text{C}\delta\text{Leu}$), 24.66 ($\text{C}\gamma\text{Leu}$), 28.13 (Me, Boc), 41.0 ($\text{C}\beta\text{Leu}$), 49.9 ($\text{C}\alpha\text{Ala}$), 50.7 ($\text{C}\alpha\text{Leu}$), 80.13 (C, Boc), 155.78 (C=O, Boc), 173.0 (C=O), 176.0 (COOH).

Acknowledgments

The authors would like to thank CONICET (Consejo Nacional de Investigaciones Científicas y Técnicas - Argentina), Universidad Nacional de Rosario (Argentina), The Royal Society of Chemistry (U.K.) and Fundación Antorchas (Argentina) for financial support.

References

1. (a) Greene, T.W.; Wuts, P.G.M. *Protective Groups in Organic Synthesis*; 3rd Edn.; Wiley: New York, 1999. (b) Kocienski, P.J. *Protecting Groups*; Thieme: New York, 1994.
2. (a) Burgess, K., Ed. *Solid-phase Organic Synthesis*; Wiley-Interscience: New York, 2000. (b) Seneci, P. *Solid-phase Synthesis and Combinatorial Technologies*; Wiley & Sons: New York, 2000. (c) Zaragoza Dörwald, F. *Organic Synthesis on Solid Phase*; Wiley-VCH, Weinheim, 2000. (d) Czarnik, A.W., Ed. *Solid-phase Organic Syntheses*; Wiley-Interscience: New York, 2001.
3. (a) Hodge, P. *Chem. Soc. Rev.* **1997**, 26, 417. (b) Yan, B. *Comb. Chem. High Throughput Screen.* **1998**, 1, 215. (c) Sherrington, D.C. *J. Chem. Soc., Chem. Commun.* **1998**, 2275. (d) Vaino, A.R.; Janda, K.D. *J. Comb. Chem.* **2000**, 2, 579. (e) Rana, S.; White, P.; Bradley, M. *J. Comb. Chem.* **2001**, 3, 9.
4. Oran, D.; Ellard, J.; Bradley, M. *J. Comb. Chem.* **2002**, 4, 1.
5. Zhang, A.J.; Russell, D.H.; Zhu, J.; Burgess, K. *Tetrahedron Lett.* **1998**, 39, 7439.
6. Beyermann, M.; Bienert, M. *Tetrahedron Lett.* **1992**, 33, 3745.
7. Sakaitani, M.; Hori, K.; Ohfume, Y. *Tetrahedron Lett.* **1988**, 29, 2983.
8. Bajwa, J.S. *Tetrahedron Lett.* **1992**, 33, 2955.
9. Dzubeck, V.; Schneider, J.P. *Tetrahedron Lett.* **2000**, 41, 9953.
10. Li, W.-R.; Jiang, J.; Joullié, M.M. *Tetrahedron Lett.* **1993**, 34, 1413.
11. Li, W.-R.; Jiang, J.; Joullié, M.M. *Synlett* **1993**, 5, 362.

12. Sakaitani, M.; Ohfume, Y. *Tetrahedron Lett.* **1985**, 26, 5543.
13. Sakaitani, M.; Ohfume, Y. *J. Org. Chem.* **1990**, 55, 870.
14. Roos, E.C.; Bernabé, P.; Hiemstra, H.; Speckamp, W.N.; Kaptein, B.; Boesten, W.H.J. *J. Org. Chem.* **1995**, 60, 1733.
15. For a solid-phase transformation of Fmoc group into O-alkyl carbamates, see: Zaragoza, F.; Stephensen, H. *Tetrahedron Lett.* **2000**, 41, 2015.
16. For a preliminary communication, see: Furlán, R.L.E.; Mata, E.G. *Tetrahedron Lett.* **1998**, 39, 6421.
17. Jiang, J.J.; Li, W.R.; Joullie, M.M. *Synth. Commun.* **1994**, 24, 187.
18. Barcelo, G.; Senet, J-P.; Sennyey, G. *J. Org. Chem.* **1985**, 50, 3951.
19. Tarbell, D.S.; Yamamoto, Y.; Pope, B.M. *Proc. Natl. Acad. Sci. USA* **1972**, 69, 730.
20. Nagasawa, T.; Kuroiwa, K.; Narita, K.; Isowa, Y. *Bull. Chem. Soc. Jpn.* **1973**, 46, 1269.
21. (a) Salvino, J.M.; Patel, S.; Drew, M.; Krowlikowski, Orton, E.; Vasant Kumar, N.; Caulfield, T.; Labaudiniere, R. *J. Comb. Chem.* **2001**, 3, 177. (b) McKeown, S.C.; Watson, S.P.; Carr, R.A.E.; Marshall, P. *Tetrahedron Lett.* **1999**, 40, 2407.
22. Atherton, E.; Sheppard, R.C. *Solid Phase Peptide Synthesis* IRL Press: Oxford, 1989, pp 112-117.
23. Furlán, R.L.E.; Mata, E.G.; Mascaretti, O.A. *J. Chem. Soc., Perkin Trans. 1* **1998**, 355.
24. Furlán, R.L.E.; Mata, E.G.; Mascaretti, O.A. *Tetrahedron* **1998**, 54, 13023.
25. Steward, J.M.; Young, J.G. *Solid Phase Peptide Synthesis*, 2nd Edn.; Pierce Chemical Company: Rockford, Illinois, 1984, p146.